This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. The $93,525.44 contract provides a 12-month silver support plan for two NextSeq 2000 sequencing systems. No set-aside was used. Illumina is a manufacturer and provider of genomic analysis instruments and reagents, and has previously received prime federal contracts and sub-awards from the NIH, CDC,...
This is a firm fixed price purchase order awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Illumina, Inc. for a service agreement renewal and co-term for a NextSeq 2000 Silver Support Plan. The potential value of the award is $29,158.67, and the period of performance runs through July 4, 2024. Illumina is a for-profit manufacturer that has previously provided a range of sequencing systems, reagents, and support services to federal...
This is a $189,332.15 firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis instruments and reagents. The contract provides an annual service agreement for four Illumina sequencing instruments, including preventative maintenance, parts, labor, reagent replacement, and technical...
This is a $48,209 firm fixed price purchase order awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. The contract provides a NEXT SEQ 2000 SILVER SUPPORT PLAN with a completion date of September 12, 2025. Illumina, a for-profit manufacturer of genomic sequencing and analysis equipment and reagents, has previously received other prime federal contracts and subcontracts from...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Illumina, Inc. for a NEXTSEQ 2000 SILVER SUPPORT PLAN. The potential value of the contract is $48,209.00, with a completion date of April 2, 2025. This contract is not set aside and is for the provision of sequencing and array-based solutions to support genomic analysis and life science research. Illumina, a for-profit...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc. for a NextSeq 2000 Silver Support Plan. The contract has a ceiling value of $32,657.70 and a period of performance through July 4, 2025. Illumina is a manufacturer of sequencing and genomic analysis instruments and has been awarded other federal prime contracts and subcontracts to provide sequencing systems, reagents, and services to support...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract provides a MiSeq Silver Support Plan with a ceiling value of $13,250.00 and an ultimate completion date of January 2, 2021. Illumina has a long history of providing sequencing systems and related products and services to support research and diagnostics across...
This is a $16,198 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc. for a MiSeq Silver Support Plan with an ultimate completion date of February 5, 2026. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis, and has been awarded previous prime contracts and subcontracts by federal...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract, valued at $12,875.00, is for sequencing services to support NIAID's research and diagnostic efforts. Illumina has previously been awarded other prime federal contracts and subcontracts by...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc. for a NextSeq 2000 Silver Support Plan and Preventive Maintenance with a total ceiling value of $23,717.81. The award does not utilize any set-aside designations. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis, and has received prior prime federal contract and sub-grant awards...